EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.
EvlaBio has raised $24.6M in total funding. The most recent round was Seed. The last funding was announced in July 2025.
EvlaBio's investors include HTGF (High-Tech Gruenderfonds), Kurma Partners, Boehringer Ingelheim Venture Fund, AdBio partners, NRW.Venture.
EvlaBio is headquartered in Zürich, Switzerland.
EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs.
EvlaBio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EvlaBio — Funding & Investors." VCBacked, July 7, 2025, https://www.vcbacked.co/company/evlabio. Accessed August 14, 2026.
VCBacked. (2025). EvlaBio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/evlabio
{{cite web |title=EvlaBio — Funding & Investors |url=https://www.vcbacked.co/company/evlabio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated